RA MEDICAL SYSTEMS INC (RMED)
US74933X3026 - Common Stock
Taking everything into account, RMED scores 3 out of 10 in our fundamental rating. RMED was compared to 195 industry peers in the Health Care Equipment & Supplies industry. RMED scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RMED is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year RMED has reported negative net income.
In the past year RMED has reported a negative cash flow from operations.
In the past 5 years RMED always reported negative net income.
In the past 5 years RMED always reported negative operating cash flow.
1.2 Ratios
RMED has negative profitability rations, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RMED has a Gross Margin of 15.56%. This is amonst the worse of the industry: RMED underperforms 82.91% of its industry peers.
RMED does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 15.56% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RMED does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RMED has more shares outstanding
The number of shares outstanding for RMED has been increased compared to 5 years ago.
RMED has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -9.32, we must say that RMED is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of RMED (-9.32) is worse than 79.90% of its industry peers.
RMED has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.32 |
ROIC/WACCN/A
WACC9.44%
2.3 Liquidity
RMED has a Current Ratio of 2.86. This indicates that RMED is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.86, RMED perfoms like the industry average, outperforming 41.21% of the companies in the same industry.
RMED has a Quick Ratio of 2.85. This indicates that RMED is financially healthy and has no problem in meeting its short term obligations.
RMED has a Quick ratio of 2.85. This is comparable to the rest of the industry: RMED outperforms 53.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.86 | ||
| Quick Ratio | 2.85 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 73.38% over the past year.
Looking at the last year, RMED shows a very strong growth in Revenue. The Revenue has grown by 221.43%.
The Revenue for RMED have been decreasing by -70.11% on average. This is quite bad
EPS 1Y (TTM)73.38%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-82.59%
Revenue 1Y (TTM)221.43%
Revenue growth 3Y-77.76%
Revenue growth 5Y-70.11%
Revenue growth Q2Q844.44%
3.2 Future
RMED is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.23% yearly.
Based on estimates for the next years, RMED will show a very strong growth in Revenue. The Revenue will grow by 1049.91% on average per year.
EPS Next Y52.85%
EPS Next 2Y40.99%
EPS Next 3Y26.23%
EPS Next 5YN/A
Revenue Next Year13964.3%
Revenue Next 2Y2408.98%
Revenue Next 3Y1049.91%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RMED. In the last year negative earnings were reported.
Also next year RMED is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as RMED's earnings are expected to grow with 26.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.99%
EPS Next 3Y26.23%
5. Dividend
5.1 Amount
RMED does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
RA MEDICAL SYSTEMS INC
NYSEARCA:RMED (8/17/2023, 7:04:01 PM)
After market: 0.5785 -0.02 (-2.61%)0.594
+0.05 (+10%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.16M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 15.56% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.86 | ||
| Quick Ratio | 2.85 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)73.38%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y52.85%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)221.43%
Revenue growth 3Y-77.76%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y